<DOC>
	<DOCNO>NCT00010244</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . It yet know regimen radiation therapy effective prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness different regimen radiation therapy treat patient localized prostate cancer .</brief_summary>
	<brief_title>Comparison Radiation Therapy Regimens Treating Patients With Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare 5-year survival rate , term clinical biological remission , patient localized prostate cancer treat two different radiotherapy regimens use different dos number fraction . II . Compare nadir PSA delay obtain nadir patient treat two regimen . III . Compare acute long-term toxicity two regimens patient . IV . Compare overall survival quality life patient treat two regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center . Patients randomize 1 2 treatment arm . Arm I : Patients receive radiotherapy seminal vesicle 46 Gy 23 fraction prostate 70 Gy 35 fraction , 5 fraction per week . Arm II : Patients receive radiotherapy seminal vesicle arm I prostate 80 Gy 40 fraction , 5 fraction per week . Treatment continue arm absence disease progression unacceptable toxicity . Quality life assess annually . Patients follow every 4 month minimum 5 year . PROJECTED ACCRUAL : A total 306 patient ( 153 per arm ) accrue study within 2.5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Localized prostate cancer : T2aT3a OR T1b T1c PSA least 10 ng/mL OR T1b T1c Gleason score 710 No T3b T4 ; positive biopsy nodal excision N0 , N bilateral removal estimate risk nodal invasion least 10 % M0 ( bone scintograph chest xray ) PSA le 50 ng/mL PATIENT CHARACTERISTICS : Age : Under 75 Performance status : WHO 01 Life expectancy : At least 10 year Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No prior invasive malignancy within past 5 year except basal cell carcinoma No social , familial , geographic obstacle would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy No concurrent biologic therapy Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : No prior hormonal therapy include adjuvant therapy No concurrent hormonal therapy Radiotherapy : No prior pelvic radiotherapy Surgery : No prior radical anterior prostatectomy cancer No prior castration</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>